ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In a span of less than a week, the US Food and Drug Administration approved two new therapies, each of which is a first-in-class treatment for its respective disease. The first to receive the nod was Provention Bio’s teplizumab, an antibody that can delay the onset of type 1 diabetes in patients 8 years and older. Days later came approval for CSL Behring’s Hemgenix, the first gene therapy for hemophilia B. The one-time treatment restores peoples’ ability to produce proteins that help with blood clot formation.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter